Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,017 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Systemic Infection Clear all

Conditions: Nosocomial Bacteremia, Nosocomial Fungemia, MRSA Colonization, MRSA Infection, VRE Colonization, VRE Infection
Interventions: Daily bathing with Chlorhexidine based product; Behavioral
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 5,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more

Conditions: Clinical Sepsis
Interventions: Sepsis Transition And Recovery (STAR), Usual care; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Septic Shock
Interventions: Angiotensin II, Norepinephrine; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Winston-Salem, North Carolina

Conditions: Septic Shock, Sepsis, Hypovolemia
Interventions: VBI-S; Drug
Lead sponsor: Vivacelle Bio; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Chandler, Arizona • Savannah, Georgia • Kansas City, Missouri + 2 more

Conditions: Septic Shock
Interventions: Thiamine and Vitamin C; Dietary Supplement
Lead sponsor: Corewell Health South; Other
Eligibility: 18 Years to 90 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Saint Joseph, Michigan

Conditions: HIV, Acute HIV Infection
Interventions: Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Sepsis
Interventions: Telemedicine; Other
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 1,191 participants
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Bacteremia, Enterobacteriaceae Infections
Interventions: Not listed
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 7 Years to 89 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Systemic Fungal Infections
Interventions: Parenteral micafungin application, Other parenteral antifungal drugs; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: Not listed
Enrollment: 40,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 6
States / cities: Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 3 more

Conditions: Human Immunodeficiency Virus Infection
Interventions: darunavir with ritonavir and fixed-dose viread+emtricitabine daily; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 21 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Candidiasis, Invasive, Candidemia, Mycoses
Interventions: Isavuconazole, Caspofungin, Voriconazole; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 18
States / cities: Birmingham, Alabama • Palm Desert, California • Sacramento, California + 15 more

Conditions: Sepsis
Interventions: Algorithm Alarm- Crystalloids, Standard of Care; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 2,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Atlanta, Georgia • Decatur, Georgia • Johns Creek, Georgia + 1 more

Conditions: Cardiovascular Diseases, Endotoxemia, Endothelial Dysfunction, Postprandial Hyperglycemia, Gut Health
Interventions: Bagel, Potato; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Shock, Hemorrhagic, Shock, Traumatic, Shock, Septic
Interventions: Polydatin Injectable; Drug
Lead sponsor: Neptunus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: fluorouracil, leucovorin calcium, topotecan hydrochloride; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: New York, New York

Conditions: Staphylococcus Aureus Bacteremia
Interventions: 514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment, Placebo plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II, Placebo plus standard IV antibiotic treatment: Phase II; Biological · Other
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Columbus, Georgia • Charlotte, North Carolina

Conditions: Sepsis, Deterioration, Clinical, Critical Illness, Early Warning Score
Interventions: Algorithm-triggered sepsis alert with structured critical care team activation; Other
Lead sponsor: Patricks Lyons; Other
Eligibility: 18 Years and older
Enrollment: 3,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Severe Sepsis With Septic Shock
Interventions: Interleukin-7, Placebo; Drug
Lead sponsor: Revimmune; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Infection, Acute Kidney Injury, Sepsis
Interventions: Piperacillin + Tazobactam, meropenem; Drug
Lead sponsor: Bassett Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 852 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Worcester, Massachusetts • Omaha, Nebraska • Cooperstown, New York + 4 more

Conditions: Staphylococcal Sepsis
Interventions: Pagibaximab (formerly BSYX-A110); Drug
Lead sponsor: Biosynexus Incorporated; Industry
Eligibility: 48 Hours to 120 Hours
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Foot Ulcer, Diabetic, Infection
Interventions: Gentamicin collagen sponge, Placebo; Drug · Other
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 86
States / cities: Anniston, Alabama • Mobile, Alabama • Mesa, Arizona + 67 more

Conditions: Septic Shock
Interventions: GIK; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Nosocomial Infections, Sepsis, Staphylococcal Infections, Candidemia
Interventions: Veronate; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 3 Days to 5 Days
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 85
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 71 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: decitabine; Drug
Lead sponsor: California Cancer Consortium; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 4
States / cities: Duarte, California • Los Angeles, California • Sacramento, California

Search by objective public record fields.

The Impact of Chlorhexidine-Based Bathing on Nosocomial Infections

Improving Morbidity During Post-Acute Care Transitions for Sepsis

Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock

A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)

Thiamine, Vitamin C and Hydrocortisone in the Treatment of Septic Shock

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

TELEmedicine as an Intervention for Sepsis in Emergency Departments

Ultra Rapid Culture Independent Detection of High-Priority Carbapenem Resistant Enterobacteriaceae Directly From Blood

Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents

Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Precision Resuscitation With Crystalloids in Sepsis

Cardiometabolic Benefits of Potatoes Mediated Along the Gut-Vessel Axis in Adults With Metabolic Syndrome

Polydatin Injectable (HW6) for Shock Treatment

Combination Chemotherapy in Treating Patients With Advanced Cancer

Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.

Hospital-Onset Sepsis Systematic Detection and Structured Interventions

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients

The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110

Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers

Rapid Administration of Insulin in Sepsis

Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants

Decitabine in Treating Patients With Melanoma or Other Advanced Cancer